

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>DENYES NANCY</u> (Last) (First) (Middle) 3545 JOHN HOPKINS COURT, SUITE 250 (Street) SAN DIEGO CA 92121 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>aTYR PHARMA INC [LIFE]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ <input checked="" type="checkbox"/> Officer (give title below) _____ Other (specify below) _____ General Counsel
	3. Date of Earliest Transaction (Month/Day/Year) 05/16/2020	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	05/16/2020		M		892	A	(1)	3,057(2)	D	
Common Stock	05/20/2020		s(3)		322(3)	D	\$3.62	2,735	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Employee Stock Option (right to buy)	\$4.06	05/26/2020		A		30,000		(4)	05/26/2030	Common Stock	30,000	\$0.00	30,000	D	
Restricted Stock Unit	(1)	05/16/2020		M		892		(5)	(5)	Common Stock	892	\$0.00	0	D	

Explanation of Responses:

- Restricted stock units (RSU) convert into common stock on a one-for-one basis.
- Includes 178 shares acquired under the Company's 2015 Employee Stock Purchase Plan (ESPP) on May 15, 2020.
- Sale made by the Reporting Person in compliance with the provisions of Rule 10b5-1 to satisfy tax withholding obligations in connection with the partial vesting of RSUs granted on May 16, 2018.
- 50% of the shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning June 26, 2020, such that these shares will be fully exercisable on May 26, 2024; 25% of the shares subject to this option will vest on May 26, 2021 if and only if a clinical development milestone is achieved by September 30, 2020; and the remaining 25% of the shares will vest on May 26, 2021 if and only if an additional clinical development milestone is achieved by September 30, 2020.
- The RSU grant vests as to one-half (1/2) of the total number of units on each one year anniversary of the grant commencing on May 16, 2019.

Remarks:

Nancy E. Denyes 05/28/2020
 ** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.